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CD4+ Th immunogenicity of the Ascaris spp. secreted products
Friederike Ebner1,3, Eliot Morrison2, Miriam Bertazzon2, Ankur Midha1, Susanne Hartmann1✉, Christian Freund2✉ and
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Ascaris spp. is a major health problem of humans and animals alike, and understanding the immunogenicity of its antigens is
required for developing urgently needed vaccines. The parasite-secreted products represent the most relevant, yet complex (>250
proteins) antigens of Ascaris spp. as defining the pathogen-host interplay. We applied an in vitro antigen processing system coupled
to quantitative proteomics to identify potential CD4+ Th cell epitopes in Ascaris-secreted products. This approach considerably
restricts the theoretical list of epitopes using conventional CD4+ Th cell epitope prediction tools. We demonstrate the specificity
and utility of our approach on two sets of candidate lists, allowing us identifying hits excluded by either one or both computational
methods. More importantly, one of the candidates identified experimentally, clearly demonstrates the presence of pathogen-
reactive T cells in healthy human individuals against these antigens. Thus, our work pipeline identifies the first human T cell epitope
against Ascaris spp. and represents an easily adaptable platform for characterization of complex antigens, in particular for those
pathogens that are not easily amenable for in vivo experimental validation.
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INTRODUCTION
Ascaris spp. infections currently affect around 820 million people
leading to impaired growth, impaired physical fitness and
cognition, while also reducing general performance, in particular
in children1. Considering the worldwide prevalence and intensity
of Ascariasis in humans, it is critical to overcome the current
limitations in controlling this parasitic infection. Improvements on
infrastructure and educational programs together with revised
mass drug administration programs will definitively contribute to
mitigate the impact of Ascariasis1. However, the ideal solution
would be the development of vaccines that prevents commonly
observed re-infection after chemotherapy2,3. Candidate vaccines to
prevent Ascaris spp. infection should be able to trigger effective
antibody responses targeting essential antigens for the parasite to
complete its life cycle4. The challenge is that these large,
multicellular and cuticularized parasites confront the host with a
complex mixture of protein antigens from which we have still very
poor knowledge on their importance for infection or their
immunogenicity. Ascaris spp. actively excrete and secrete complex
mixtures of molecules, excretory secretory (ES) products, which are
essential in parasite’s communication with its host, and shaping
the host immune response5–7. The ES proteins comprise critical
targets for vaccination in animal models and are expected to bear
targets for vaccination in humans as well (reviewed in ref. 2).
Interestingly, animal models have clearly shown the dependency
on MHCII-restriction for the target of the antibody responses8–10.
Thus, the deterministic nature of T-B cell responses—which implies
that CD4+ Th cell epitopes define the target of the antibody
response—should contribute to define targets for the design of
candidate subunit vaccines11. Therefore, identifying the epitopes
that are involved in the host’s natural CD4+ Th cell responses is
essential to understand, monitor or modulate adaptive immune
mechanisms that orchestrate Ascaris spp. expulsion.
CD4+ Th cells recognize antigenic peptides presented by the
major histocompatibility complex class II (MHCII) proteins
expressed on antigen-presenting cells (APC). Peptides from
antigens only become immunogenic when they are selected for
presentation, and remain bound to MHCII molecules for a
sufficient time to allow T cell surveillance. Thus, the abundance
of antigens, their resistance to degradation and the affinity for the
MHCII will define the potential immunogenicity of any peptide. To
date, conventional in silico approaches predict peptide-MHC
(pMHC) affinity mostly based on MHC pocket occupation by the
peptide amino acids12,13, which is usually not very accurate for
MHCII. Indeed, the IEDB CD4+ T cell immunogenicity prediction
tool only reaches 50% of the immune response for those peptides
below the percentile 20. However, these approaches ignore
relevant aspects affecting epitope selection, such as the dynamics
of peptide-MHCIIs14,15 (pMHCII), the peptide-editing function of
HLA-DM16, and the influence of proteolytic activities on antigen
presentation17. Although integrating proteolytic degradation
improves the current conventional methods18, a robust in silico
ranking of the most effectively presented peptides is still elusive.
Experimental approaches based on recombinant proteins or
subcellular fractions containing endosomal compartments rich
on MHCII have been applied to define epitope selection on single
antigens19,20. Culture of primary DC and quantitative immuno-
peptidomics of infected cells has also been used to define CD4+
Th cell epitopes from Listeria monocytogenes in mouse
21. However,
the complex infection cycle of Ascaris spp. and of its antigens pose
a considerable challenge for any of these methods. Consequently,
to date, there is no experimental set-up described to define the
CD4+ Th immunogenicity of complex antigenic mixtures as
nematode ES.
RESULTS AND DISCUSSION
During infection Ascaris parasites confront the host with a mixture
of the ES from female (ESF) and male (ESM) worms, which are
considered to bear candidates for subunit vaccines22. Parasitic
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nematodes are suggested to be polygamous and often show
female-biased sex ratio within the distribution in a host. Analyzing
female and male ES antigens separately for their influence on
CD4+ Th cell responses presents an unbiased approach to account
for pathogen gender-heterogeneity during infection, sexual
dimorphism (e.g., size) and gender-associated genes/proteins as
reported previously for other parasitic nematodes6,7,23,24.
We generated human T cell lines from healthy volunteers
reacting to ESF or ESM antigens using the antigen-specific T cell
enrichment and expansion as described by Bacher et al.25
(Supplementary Fig. 1a). This approach helped to overcome the
expected low in vivo frequency of any potential Ascaris ES-specific
CD4+ Th cells in healthy (uninfected) donors. The presence of
reactive T cells and its low frequency was confirmed by CD40-L
staining (Supplementary Fig. 1b). CD40-L, is specifically expressed
by CD4+ Th cells shortly after TcR-mediated antigen recognition
irrespectively of the restricting MHC allele and can be used to
assess and enrich antigen-specific T cells26. Re-stimulation of the
generated cell lines specific for ES antigens resulted in a
remarkable increase on CD40-L+ cells when compared to the
corresponding controls (Fig. 1a). Upregulation of CD40-L and
CD40-L/cytokine co-expression (Supplementary Fig. 1c) after re-
stimulation confirms a functional CD4+ Th phenotype of Ascaris-
reactive T cells. Interestingly, when testing reactivity of T cell lines
for the mismatched ES antigen we could detect a lower
proportion of reactive T cells, suggesting the presence of gender
specific-T cell responses (Fig. 1b).
The observed gender-specific T cell responses motivated us to
perform a proteomic characterization of ESF and ESM antigens6,7
(Fig. 1c–e). Our aim was to identify ESF and ESM antigens bearing
potential CD4+ Th epitopes. By combining the use of the
exponentially modified Protein Abundance Index (emPAI) with
16O/18O-labeling (Fig. 1d) we defined the ESM and ESF composi-
tion, thereby retrieving absolute protein abundances of ESM and
ESF extracts (Fig. 1e), and the relative difference between them
(Fig. 1e). This analysis yielded additional information regarding the
differences in abundance between ESF and ESM (Supplementary
Table 1) in comparison to the previously described dataset7. The
difference in the number of protein sources found here when
compared with the previous study (175 previously vs. 254 in our
case) arises from our conservative approach when considering the
source of tryptic peptides. Rather than selecting a single leading
protein, we explicitly kept protein entries with small differences in
their primary sequences but which are not clearly distinguishable
by conventional shotgun MS. This characterization could be used
either as a reduced sampling space for potential CD4+ Th cell
epitopes vs. the whole Ascaris spp. predicted proteome, or as an
internal control for further experiments in which these 250
proteins are expected to be the immunogenic determinants of
host responses to Ascaris spp. We found large differences in the
abundance of proteins either within a single extract or between
ESM and ESF (fold-differences up to 103 for emPAI and 107,
respectively).
Fig. 1 CD4+ Th cell activation in Ascaris ES antigen-specific T cell lines and ES antigen composition. a For generating Ascaris suum ES-
specific T cell lines, PBMCs from healthy donors were stimulated with 40 µg/mL ES antigen for 6 h, enriched for CD40-L+ cells and expanded
for 2 weeks (see Supplementary Fig. 1a). Expanded ES-reactive T cells were re-stimulated with or without (w/o) ESF or ESM-antigen-primed,
CD3-depleted APC and percentages of CD40-L+ antigen-reactive T cells among CD4+ cells are indicated above gates. b Percentages of CD40-
L+ antigen-reactive T cells among A. suum ES-reactive T cell lines re-stimulated with ESF or ESM antigen, or with mismatched ES antigens for
n= 3–5 different donors (left: mean with SEM, right: paired t-test). c Model antigenic mixtures derived from Ascaris ES products are different in
protein composition. SDS-PAGE of ES male (ESM) and ES female (ESF) mixtures (40 μg of antigen loaded per well). d A mass-spectrometry-
based approach used to determine composition of male and female ES products. The emPAI and the ESF vs. ESM (16O/18O) ratios are defined
after tryptic digest defining the total abundance and the differences between ESF and ESM. e Volcano plot showing differences in protein
composition determined by mass spectrometric analysis. The depicted log2-fold intensity difference (ESM vs. ESF) represents the difference in
geometric mean values from 18O labeling. On the y axis the –log (p-value) for the difference observed is indicated. Blue symbols indicate ESF-
enriched and red corresponds to ESM-enriched. The different size of the corresponding symbols indicates the determined emPAI value as
shown in the legend.
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The identification of CD4+ Th cell epitopes from the ES
products, with 1.5 × 105 potential 15-mers, represents a challenge.
In silico, one could make use of binding predicting tools such as
NetMHCIIPan reducing the number of candidates since only
strong and weak affinity binders are expected to be immunogenic.
For a set of seven common MHCII allotypes NetMHCIIPan defines
between 1.2 × 104 to 3.9 × 104 peptides for the ES (Supplementary
Fig. 2a). More sophisticated approaches as the IEDB CD4 T cell
immunogenicity prediction tool27 (IEDBcd4) rely on a combination
of binding affinity prediction, and neural network trained on
F. Ebner et al.
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experimentally validated epitopes from the IEDB. Thus, candidates
ranked in the first 20th percentile would bear around half of the
immunogenic candidates of an antigen. In this case, the number
of CD4+ Th cell epitope candidates within the ES lies in the range
of 800–1500 for the same MHCII allotypes (Supplementary Fig. 2b).
However, these methods ignore relative and total protein
abundances that could be of relevance when assessing the
immunogenicity of ESF and ESM. Experimentally, the most popular
approaches rely on the identification of pathogen-derived MHCII-
bound peptides by MS. Either cell cultures or animal models
infected with the pathogen, or provided with the corresponding
antigens, are the sources for isolation of MHCII-peptides. The
availability of adequate infection models and the lack of biological
replicating capacity of the ES poses a major challenge for any of
such approaches. We hypothesized that an in vitro experimental
approach recapitulating key events of antigen presentation such
as proteolysis of antigens by cathepsins and catalyzed peptide
exchange by HLA-DM, should contribute to define potential CD4+
Th epitopes. We reasoned that this minimalist experimental
approach described by Sadegh-Nasseri’s group19 should facilitate
the identification of potential epitopes when using complex
antigenic mixtures. Indeed, using this system, the lower back-
ground of self-peptides will benefit the MS identification of
pathogen derived antigenic peptides when compared to mass
spectrometry analysis of MHCII-associated peptidomes from cell
culture or in vivo samples.
We used for our experiments the ES antigens (ESM or ESF), two
common MHCII allotypes (DRB1*07:01 or DRB1*15:01, Supple-
mentary Fig. 2c) preloaded with the placeholder Class II invariant
chain peptide-CLIP and HLA-DM, which functions as peptide-
editor16 (details in Supplementary Fig. 2d) and the commercial
proteases previously described19 (Fig. 2a). Recombinant MHCII
proteins are resistant to proteases (Fig. 2a) and can be further
pulled-down from the mixtures to elute and determine the bound
peptides by LC-ESI-MS. We used MaxQuant for peptide identifica-
tion considering a customized database that includes all the
potential entries derived from the Ascaris genome, and the
molecules of the in vitro reconstitution system (MHCII, HLA-DM
and proteases) (Fig. 2b). As expected, the majority (>99.0%) of the
peptides belong to protein sources identified in the ES. The
information on MS1 intensity for each identified peptide was used
by our recently described epitope analysis tool, PLAtEAU28, to
define consensus peptides including their relative abundance for
each series of peptides that contain a common core but vary in
the length of their N-terminal and C-terminal extensions (Fig. 2b).
This experimental workflow dramatically reduces the number of
potential CD4+ Th epitopes to less than 10
3 peptides for all
conditions, which once analyzed with PLAtEAU resulted in around
150 candidate epitopes for each condition (details given in Fig. 2c
and Supplementary Fig. 2e). The full list of peptide identified
consists of a total of 335 potential T cell epitopes, which were
annotated based on the abundance of the corresponding protein
source, the predicted affinity for each allotype, and whether the
binding core is found in any peptide defined by the IEDBcd4
(Supplementary Table 2). There is a considerable overlap between
the consensus peptides selected by each allotype for the ESF and
ESM, and around one third are found in the lists of IEDBcd4
predicted immunogenic peptides (Fig. 2c and Supplementary Fig.
2f). More interestingly, there are certain peptides found exclusively
enriched in for either ESF or ESM. The presence of predicted weak
and high affinity binders increases from 10 and 1% in the pool of
all potential peptides of the ES to 20 and 7% in the experimentally
determined peptides, respectively. The presence of peptides with
no predicted affinity for the MHCII allotypes used may represent
mainly intermediate steps of the antigen processing reactions that
are stable enough to overcome the immunoprecipitation process
and that would be exchanged under more dynamic conditions of
protein turnover in the living cell. Thus, the protein concentrations
available under the test-tube conditions assayed may represent a
limiting factor. Hierarchical clustering analysis of the annotated
potential epitopes based on their abundance reveals that both
MHCII molecules selected mostly epitopes from proteins with
intermediate and high emPAI values, and in particular from those
enriched (e.g., ESF:ESM ratio > 2) in the respective antigen source
(ESM or ESF) (Volcano plots in Fig. 2d and Supplementary Fig. 2g).
We selected a limited set of peptides that would allow us to test
the performance of the reconstituted in vitro system on its own
and in comparison to in silico prediction tools to define
immunogenic candidates (Figure 2e). We initially selected a
limited set of six candidates including the Ov17 (F1LAR2127–146)
consensus peptide defined exclusively under DRB1*07:01 + ESF
conditions (predicted to be immunogenic by IEDBcd4 but with
weak affinity for the restricting allele). This peptide represents an
ideal candidate to prove the selectivity and performance of our
Fig. 2 The use of a reconstituted in vitro antigen processing facilitates the detection of CD4+ Th cell epitopes. a ES products are incubated
in vitro with recombinant proteins and adequate buffer conditions. Proteolytic activities used degrade most of the components of the
reactions except for MHCII proteins which are subsequently pull down using a conformation specific antibody (L243). b MaxQuant is used for
their identification and PLAtEAU defines series of nested peptides and retrieve the consensus peptides and corresponding MS1 intensities
according to the MaxQuant output. For each peptide a relative abundance value is retrieved based on the MS1 intensity and the total ion
current from the run. This approach yields a list of candidate epitopes with relative abundance values and predicted affinities. c Summary of
the performance of the experimental determination of candidate antigens for each condition tested. The overlap between the peptide sets
(based on predicted binding cores to facilitate comparisons) for each allotype and ES antigen, and the predicted IEDB immunogenicity score is
shown as Venn Diagrams (sized according to numbers, the IEDB set consists of 3678 entries and it is cut in this figure but shown in full in
Supplementary Fig. 2f). d Mapping of the identified potential epitopes to their corresponding protein sources using the intensity color code
shown in the legend. e Summary of peptides used to evaluate the performance of the reconstituted in vitro system. The peptide sequence is
shown in the first column and underlined is shown the binding core predicted for DRB1*07:01. The corresponding protein source with the
amino acid positions covered by the peptide are indicated in the second column. Abbreviated uniprot names are provided. Last columns
include the relative and total abundance of each protein sources and the predicted binding affinity for DRB1*07:01 and whether any peptide
with the same binding core (underlined) is predicted to be immunogenic by IEDBcd4 prediction tool. f Representative dot blot example for a
ESF antigen-specific T cell line generated from an healthy DRB1*07-typed volunteer and re-stimulated with either whole ES antigen (40 µg/
mL), no antigen (w/o) or a pool of synthetic peptides (25 µg/mL for each peptide) selected from the in vitro reconstituted HLA-DRB1*07:01
experimental data set (f). g Summarizes CD40-L frequencies among CD4+, indicative for peptide recognition by CD4+ T cells, for whole ES
antigen, peptide pool and single peptide re-stimulations. Peptide sequences are indicated in Table (f). Combined are data from the same
healthy, DRB1*07-typed volunteer from n= 3 separate experiments with n= 2 separate re-stimulations (1st peptide set) or n= 1 experiment
with n= 3 separate re-stimulations (2nd peptide set). CD40-L frequencies per experiment were corrected for individual background CD40-L
expression of w/o antigen/w/o APC controls (mean with SEM). h Representative dot blots of an Ascaris ESF-specific, DRB1*07T cell line
analyzed for Ascaris ESF peptide-specific tetramer staining. Left side indicates overall frequency of ESF antigen specific CD4+ cells after
expansion compared to control. Right side shows corresponding tetramer staining with DRB1*07:01-Tet-CLIP (control), Tet-RtBP and TetOv17
gated on CD4+ T cells after expansion. Italic numbers indicate calculated Tet+ frequency relative to proportion of ESF antigen-specific T cells.
F. Ebner et al.
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experimental approach. Experiments on swine and mouse models
have shown the potential of the OV17 antigen (F1LAR2/As16) for
conferring protection to Ascaris spp. infection29–31, and further-
more the restricting allele reaches up to 9% of the global
population and even higher frequencies in Ascaris spp. endemic
areas (up to 10.5% in Africa and 15% in Asia)32. Other peptides
included in this list comprise candidates excluded by either the in
silico or experimental approaches. We queried whether the TcR
pool present in healthy individuals would respond to these
candidates. We derived ESF T cell lines from a healthy, DRB1*07-
typed volunteer and assessed CD40-L expression after re-
stimulation with either whole antigen, the selected pool of six
peptides, or single peptide loaded APCs (Fig. 2f). Strikingly, we
found that OV17, and to a lower extent PABA1_1 peptides, which
we selected as potential CD4+ Th cell epitopes experimentally and
also considered as potentially immunogenic by IEDBcd4 yield a T
cell response above the background (dashed line) (Fig. 2g). We
further verified the specificity of the experimental approach by
testing this same set of peptides using ESF expanded cell lines
from a DRB1*03:01; DRB1*15:01 volunteer (Supplementary Fig.
2h). We additionally tested a second set of peptides including
candidates found by our experimental approach and neglected by
either one or both in silico tools (Fig. 2e). Interestingly, we confirm
the immunogenicity of four candidates excluded by the IEDBcd4
and with weak affinity prediction for DRB1*07:01 (Fig. 2e, g). Note
that again in these experiments we re-confirm the Ov17 peptide
as a prime candidate of immunogenicity in the DRB1:07:01
background. In summary, the proposed experimental approach
outperforms to the use of either prediction tools on their own.
Considering the co-dominant expression of other HLA genes in
the donor-derived cell lines, the reactivity observed could arise
from the presentation of the corresponding peptides by any
MHCII allotype present in the APCs. We confirmed the DRB1*07:01
restriction for the presentation of the OV17 peptide by tetramer
staining of ESF CD4+ T cell lines. A significant pool of CD4+ T cells
responding to this peptide is detected when it is displayed by
DRB1*07:01 tetramers compared to control tetramers (DR7CLIP or
DR7RtBP tetramers; Fig. 2h and Supplementary Fig. 1e). Of note, the
overall low frequency of DRB1*07:01-TetOv17
+ cells can be
explained by the low frequency of whole antigen-reactive T cells
for the cell line applied in that assay (only 6.9% CD40-L+, Fig. 2g),
but still reflect that 2.8% of all ESF reactive T cells bind
DRB1*07:01-TetOv17.
Together, we demonstrate that a reduced set of in vitro and
ex vivo experiments is extremely useful to define human CD4+ Th
cell epitopes from complex antigenic mixtures bypassing the need
of animal models33 or immunization in humans34. The use of
controlled redox potential and/or the gamma-interferon-inducible
lysosomal thiol reductase35 should further contribute to improving
the presented approach by facilitating access to disulfide-bonded
epitopes. However, presentation of the selected candidates
already represents an excellent platform for testing the impor-
tance of specific antigen processing factors such as HLA-DM36 or
its competitive inhibitor HLA-DO37. Conditions can be tuned to
include distinct MHC allotypes or combinations thereof, and the
nature of the antigen can reach from single proteins to complex
mixtures derived from secretomes, complete pathogens or cellular
lysates. From a biological point of view we characterize the OV17
(F1LAR2127–146) epitope as a human CD4
+ Th cell epitope for
Ascaris spp. and show its restriction by the DRB1*07 allotype.
Immunization with this antigen in animal trials elicits considerable
protective immunity to Ascaris spp. including specific antibodies
and CD4+ Th cells
29–31. It will thus be of great importance to
further characterize immune responses against the OV17/AS16
peptide in either carriers or non-carriers of DRB1*07:01 to confirm
the potential of these antigen for vaccination. Another interesting
candidate is PABA110, showing a completely different peptide
selection pattern for the two alleles used, with a considerably
higher number of peptides selected by DRB1*15:01 when
compared to DRB1*07:01 (7 vs. 1 respectively). Prospectively, the
stage is then set to investigate a pooled sample of a limited
number of antigens to profile the T cell immune status of infected
individuals. Furthermore, gaining access to HLA-typed material
will contribute to define the deterministic nature of B-T cell
responses to complex antigens to rationalize the development of
vaccine subunits to Ascaris spp.
METHODS
Antigen preparation
Excretory-secretory (ES) antigens were prepared from worm culture
supernatants of male and female adult Ascaris spp. worms obtained from
a local slaughter house. In brief, worms were separated by sex and washed
several times in a balanced salt solution (BSS) containing antibiotics and
used as culture media for adult worms (127mM NaCl, 7.5 mM NaHCO3,
5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 200 U/mL penicillin, 200 μg/mL
streptomycin, 50 μg/mL gentamicin, 2.5 μg/mL amphotericin B) and kept
at 37 °C with 5% CO2. Media was replaced on a daily basis, sterile filtered
through a 0.22 μM vacuum-driven filter system and collected for ES
antigen preparations starting 48 h after beginning of worm culture and
finally stored at −20 °C until further use. Worm culture supernatants
collected over 1 week were further concentrated using centrifugal protein
concentrators with a 5 kDa MWCO (Vivaspin, Sartorius, Göttingen,
Germany) to obtain the final, concentrated ESF antigen (from female
worms) and ESM (from male worms).
Mass spectrometry
Peptide mixtures were analyzed by a reversed-phase capillary system
(Ultimate 3000 nanoLC) connected to an Orbitrap Velos (Thermo Fischer)
using conditions and settings described in the ref. 28. In brief, peptides
reconstituted in 0.1% (v/v) TFA, 5% (v/v) acetonitrile, and 6.5 µL were
loaded into a reversed-phase capillary nano liquid chromatography system
(Ultimate 3000, Thermo Scientific, USA) connected to an Orbitrap Velos
mass spectrometer (Thermo Scientific). LC separation was performed on a
capillary column (Acclaim PepMap100 C18, 2 μm, 100 Å, 75 μm i.d. × 25 cm,
Thermo Scientific) at an eluent flow rate of 300 nL/min. Mobile phase A
contained 0.1% formic acid in water, and mobile phase B contained 0.1%
formic acid in acetonitrile. The column was pre-equilibrated with 3%
mobile phase B followed by a linear increase up to 50% of mobile phase B
in 50min. Mass spectra were acquired in a data-dependent mode utilizing
a single MS survey scan (m/z 350–1500) with a resolution of 60,000 in the
Orbitrap, and MS/MS scans of the 20 most intense precursor ions in the
linear trap quadrupole.
For quantitative proteomics, we used 16O/18O-labeled samples. Male and
Female ES products (ESM and ESF, 50 μg) were resolved in SDS-PAGE
(4–20%). Each lane was cut into ten pieces of equal size in a parallel
fashion. In gel tryptic digestion and 16O/18O labeling was performed as
following a protocol as described in38. Briefly, gel bands were incubated
with 50 ng trypsin in 15 μL 50mM ammonium bicarbonate buffer in the
presence of heavy (H2
18O) and light (H2
16O) water overnight at 37 °C.
Residual trypsin activity was inactivated by adding 10 μL of 0.5% TFA in
acetonitrile. Matching heavy and light samples from either Male and
Female ES were mixed before drying the samples in a Speed-Vac. Samples
were reconstituted in 10 μL 0.1% (v/v) TFA and 5% (v/v) acetonitrile before
measurements. Peptide identification was performed using Mascot Distiller
(version 2.4.3.3) software. Data were searched against the Uniprot Ascaris
spp. protein database (March 2017). The mass tolerance of precursor and
sequence ions was set to 10 ppm and 0.35 Da, respectively. For
quantification, only unique peptides were used.
Peptides eluted from the reconstituted in vitro antigen processing
system were measured as described and MaxQuant software (version
1.5.2.8) was used for peptide identification. Customized databases
featuring reviewed and non-redundant Uniprot Ascaris spp. proteins from
uniprot were used (accessed March 2017) for the in vitro reconstituted
experiments to which we included all other recombinant proteins used in
the assay, namely human cathepsins, HLA-DR2 and HLA-DR7, as well as
HLA-DM. No enzyme specificity was used for the search, and a tolerance of
10 ppm was allowed for the main ion search and 50 ppm for the MSMS
identification The “match between runs” feature was enabled. The FDR was
set at 0.01 (1%). Reverse IDs and known contaminants like keratins were
filtered before further data analysis.
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NetMHCIIPan 3.2 was used to predict peptide binding to the indicated
HLA-DR allotypes. The protein database generated upon the MS analysis
(only quantified proteins) was loaded into the webserver using a 2 and
10% cutoff for strong and weak binders (unless otherwise indicated).
Constructs, protein expression, and purification
DNA constructs encoding HLA molecules used in this study have been
generated according to the sequences available in the IMGT/HLA database
(http://www.ebi.ac.uk/ipd/imgt/hla/). The cDNAs encoding the different
HLA subunits were cloned into the pFastBacDual. Recombinant proteins
were expressed in Sf9 cells infected at an MOI of 5 for 72 h. Supernatants
were concentrated and dialyzed (in PBS) using a Vivaflow200 tangential
filter. To purify the target proteins by immunoaffinity chromatography the
concentrated and buffer exchanged concentrates were applied to either
an anti-HLA-DR-FF-sepharose or M2 anti flag (Sigma)16 for HLA-DR and
HLA-DM, respectively.
Depending on the application, HLA-DR molecules were further treated
prior to their use with only Thrombin (20 U/mg protein; for tetramer
preparation) or with Thrombin and V8 protease (10 U/mg; in vitro
reconstituted system) for 2 h at 37 °C. Subsequently proteases were
inactivated by adding Complete protease inhibitor cocktail (Roche) and
further gel-filtrated, while HLA-DM proteins were directly subjected to gel
filtration. Both types of HLA proteins were gel-filtrated in a Sephadex S200.
Fractions containing the proteins of interest were pooled and concen-
trated with Vivaspin 10 KDa MWCO spin filter.
Peptide selection and synthesis
The complete list of peptides obtained after PLAtEAU analysis for all
experiments was loaded into excel as a single list. We used the excel
random selection function to generate a list of four peptides from the
whole dataset. The corresponding sets of four peptides (500 iterations)
were screened to define those with two peptides originating from the
same antigen (ESF or ESM) and found in one set of experiments (DRB*01:07
or DRB*15:01). An additional criteria included the presence on the set of
four peptides of at least one peptide not found in the corresponding
experiment (used as control). The corresponding list of peptides indicated
arises as the one fulfilling these criteria and having the larger distance
between pIm values. Synthetic peptides were subsequently purchased
from Peptides and Elephants (Berlin, Germany). Purity as stated by the
vendor was more than 95%. All peptides were protected in their N-termini
and C-termini by addition of an Ac and NH2 group, respectively.
In vitro reconstituted antigen processing system
The cell-free reconstituted in vitro system described by Sadegh-Nasseri
et al.19 was modified according to the specific needs of the experiments.
HLA molecules (1 μM) together with the candidate antigens (200 μg/mL)
and HLA-DM (0.25 μM) were incubated for 2 h at 37 °C in citrate phosphate
50mM pH 5.2 in the presence of 150mM NaCl. Cathepsins were added to
reaction mixtures after incubation with L-Cysteine (6 mM) and EDTA
(5mM). Cathepsin B (Enzo), H (Enzo), L (Enzo), and S (Sigma) were used for
our in vitro experiments at molar ratios (cathepsin:substrate) ranging from
1:250 to 1:500. The final reaction mixture was incubated at 37 °C for 2–5 h.
Afterwards the pH was adjusted to 7.5 and Iodoacetamide was added
(25 μM). Immunoprecipitation (IP) of the pMHCII complexes was performed
using L243 covalently linked to Fast Flow sepharose. Peptides were eluted
from purified MHCII adding TFA 0.1% to the samples. Peptides were
separated from the MHCII molecules by using Vivaspin filters (10 kDa
MWCO) and a subsequent reverse phase C18 enrichment. The filtrates
were further lyophilized and resuspended for mass spectrometry analyses
in a mixture of H2O (0.94):AcN (0.05):TFA (0.01).
Cell isolation and stimulation
Permission for working on human primary cells was obtained for the study
“Functional characterization of human Ascaris spp. specific CD4+ T cells“
(ethic committee of Charité—Universitätsmedizin Berlin, EA1/190/16).
DRB1 background-typed PBMC were obtained from healthy lab volunteers.
Peripheral blood mononuclear cells (PBMC) were isolated by density
gradient centrifugation over human Pancoll (1.077 g/mL, PAN-Biotech,
Aidenbach, Germany) and rested over-night in serum-free RPMI-1640 sup-
plemented with 100 U/mL penicillin and 100 µg/mL streptomycin (all from
PAN-Biotech, Aidenbach, Germany). For enrichment, 2 × 107 PBMC/mL/well
were stimulated for 6 h with excretory-secretory antigen mixtures of
female Ascaris spp. worms (ES antigen F, 40 µg/mL) in the presence of
CD40 (clone HB14, 1 µg/mL functional grade pure, #130-094-133, Miltenyi
Biotec, Bergisch Gladbach, Germany) and CD28 (clone CD28.2, 1 µg/mL,
#555725, BD PharmingenTM, NJ, US). Following stimulation, antigen-
specific T cells were separated using the CD154 MicroBead Kit (#130-
092-658, Miltenyi Biotec, Bergisch Gladbach, Germany) according to the
manufacturer’s suggestions. That included labeling first with CD154-biotin
and magnetically anti-biotin microbeads in a second step followed by
enrichment using MS MACS columns (Miltenyi Biotec, Bergisch Gladbach,
Germany).
For assessing precursor frequencies of Ascaris ES antigen F specific CD4+
T cells, PBMC were stimulated as described above and Brefeldin A (3 µg/mL,
Thermo Fisher Scientific) was added after the first 2 h of stimulation.
Generation of Ascaris suum ES antigen-specific T cell lines and
restimulation
The generation of Ag-specific T cell lines was performed as described by
Bacher et al.25. In brief, the stimulated and isolated CD154+ Ascaris ES
antigen F-specific T cells were cultured 1:100 with autologous, mitomycin
C (Sigma-Aldrich) treated feeder cells in X-VIVO™ 15 (Lonza, Basel,
Switzlerland) supplemented with 5% human AB serum (PAN-Biotech,
Aidenbach, Germany), 100 U/mL penicillin, 100 μg/mL streptomycin (PAN-
Biotech, Aidenbach, Germany), and 50 ng/mL IL-2 (PeproTech, NJ, US). Cells
were expanded for 14 days and culture medium was replenished with IL-2
containing media when needed. For restimulation after 14 days, auto-
logous PBMC were CD3-depleted using BD FACSAria™ III cell sorter or CD3-
bead MACS and co-cultured 1:1 with expanded T cell lines in the presence
of the indicated antigens. For assessing the frequency of total Ascaris ES
antigen F and/or M reactive T cells after expansion, co-cultured cells were
restimulated with 40 µg/mL ES antigen F for 6 h. For addressing peptide
specificities, restimulation was performed with single, synthetic peptides
(25 µg/mL) or a pool of all peptides (25 µg/mL of each peptide). Brefeldin A
(3 µg/mL) was added after the first 2 h of stimulation.
Antibody staining and flow cytometric analysis
The following monoclonal antibodies reactive with human species were
used for staining: CD8-VioGreen (BW135/80, cat.: 130-113-726, 1:50), CD4-
APC-Vio770 (VIT4, cat.: 130-113-211, 1:50), CD154/CD40L-PE-Vio770 (5C8,
cat.: 130-096-793, 1:10), CD20-VioGreen (LT20, cat.: 130-113-379, 1:50),
CD14-VioGreen (TÜK4, 130-113-153, 1:50) (all from Miltenyi Biotec, Bergisch
Gladbach, Germany);
IL-13-FITC (PVM13-1, cat.: 11-7139-42, 1:20 or 85BRD, cat.: 11-7136-42,
1:20), IL-4-PE (8D4-8, cat.: 12-7049-42, 1:20) (all from Thermo Fisher
Scientific); TNFa-Pacific Blue (MAb11, cat.: 502920, 1:100), IFNg-PerCp-Cy5.5
(4S.B3, cat.: 502526, 1:20), CD3-APC (Okt3, cat.: 17-0037-42, 1:50) (all from
Biolegend, San Diego, CA, US). Fixation and permeabilization were
performed using the Foxp3 Transcription Factor Staining Buffer Set
(Thermo Fisher Scientific) according to the manufacturer’s suggestions
followed by intracellular cytokine and CD154/CD40-L staining. Fixable
viability dye was used in eFluor-506 (cat.: 65-0866-14, 1:1000, Thermo
Fisher Scientific).
Cells were acquired using BD FACSCanto II (with Diva software,
Heidelberg, Germany) and post-acquisition data analysis was carried out
using FlowJo software (TreeStar, Ashland, OR, US).
Tetramer preparation and staining
Purified recombinantly expressed HLA molecules were treated with
Thrombin and subsequently subjected to size exclusion chromatography
(Sephadex S200). The placeholder peptide CLIP was exchanged by the
indicated peptides incubating HLA molecules with 50 molar excess of the
desired peptide for 72 h in the presence of molecular loading enhancers. In
brief, the FR dipeptide (150 μM) and AdaEtOH (100 μM) were used to
promote CLIP exchange for the corresponding peptides. After gel filtration
the peptide loading of HLA-II complexes was verified by MS. The generated
peptide HLA class II complexes were biotinylated in a BirA sequence (DRB
chain) using a BirA ligase (Avidity). The Biot-peptide-HLA class II complexes
were then used to generate tetramers using Streptavidin-PE. Tetrameric
complexes were finally separated by gel filtration and stored in PBS+
NaAz (0.02%).
For peptide-specific tetramer staining, expanded cells were incubated in
sodium azide (5 mM) containing X-VIVO™ 15 (Lonza) supplemented with
5% human AB serum (PAN-Biotech, Aidenbach, Germany), 100 U/mL
penicillin, 100 μg/mL streptomycin (PAN-Biotech, Aidenbach, Germany) for
F. Ebner et al.
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2 h at 37 °C and 5% CO2 in the presence of the PE-SAv-Tetramers specific
for CLIP, Ov17, or RtBp at final concentrations of 20 µg/mL. Following
incubation, cells were washed and counterstained for CD8, CD4, CD20,
CD14, and viability.
Statistical analysis
GraphPad Prism 7.0 software (GraphPad Software San Diego CA, USA) was
used in general for statistical analysis. Variance was calculated with the
two-way ANOVA method. The null hypothesis was rejected when the p
value was lower than 0.05.
Perseus software39 was mainly used to analyze the MS data. Epitopes
identified by the PLAtEAU algorithm (% Intensity from the TIC) were loaded
as matrixes into Perseus. Data was log2 transformed and missing values
were imputed as 0. The resulting matrices were plotted as heat-maps.
Columns were hierarchical clustered with “average” as agglomeration
method and “Pearson correlation” as distance matrix. Rows were ordered
by hierarchical clustering using “average” as agglomeration method and
“euclidean” as distance matrix. Epitopes eluted from each experimental
condition were grouped and used to define the mean intensity value for
each peptide or epitope. p values were calculated based on the observed
intensities using t-test, in this case an FDR of 0.01 and a S0= of 2
were used.
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this article.
DATA AVAILABILITY
The mass spectrometry proteomics data have been deposited to the ProteomeX-
change Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE
partner repository40 with the dataset identifier PXD015924 and PXD015012.
Constructs for the recombinant expression of MHCIIs are available upon request.
The PLAtEAU algorithm can be retrieved from https://github.com/e-morrison/plateau,
or used as a webtool at: https://plateau.bcp.fu-berlin.de/.
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